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Abstract
Background: British women are increasingly delaying childbirth. The proportion giving birth over the age of 35
rose from 12% in 1996 to 20% in 2006. Women over this age are at a higher risk of perinatal death, and antepartum
stillbirth accounts for 61% of all such deaths. Women over 40 years old have a similar stillbirth risk at 39 weeks as
women who are between 25 and 29 years old have at 41 weeks.
Many obstetricians respond to this by suggesting labour induction at term to forestall some of the risk. In a national
survey of obstetricians 37% already induce women aged 40–44 years. A substantial minority of parents support
such a policy, but others do not on the grounds that it might increase the risk of Caesarean section. However trials
of induction in other high-risk scenarios have not shown any increase in Caesarean sections, rather the reverse. If
induction for women over 35 did not increase Caesareans, or even reduced them, it would plausibly improve
perinatal outcome and be an acceptable intervention. We therefore plan to perform a trial to test the effect of such
an induction policy on Caesarean section rates.
This trial is funded by the NHS Research for Patient Benefit (RfPB) Programme.
Design: The 35/39 trial is a multi-centre, prospective, randomised controlled trial. It is being run in twenty UK
centres and we aim to recruit 630 nulliparous women (315 per group) aged over 35 years of age, over two years.
Women will be randomly allocated to one of two groups:
Induction of labour between 390/7 and 396/7 weeks gestation.
Expectant management i.e. awaiting spontaneous onset of labour unless a situation develops necessitating either
induction of labour or Caesarean Section.
The primary purpose of this trial is to establish what effect a policy of induction of labour at 39 weeks for nulliparous
women of advanced maternal age has on the rate of Caesarean section deliveries. The secondary aim is to act as a
pilot study for a trial to answer the question, does induction of labour in this group of women improve perinatal
outcomes? Randomisation will occur at 360/7 – 396/7 weeks gestation via a computerised randomisation programme at
the Clinical Trials Unit, University of Nottingham. There will be no blinding to treatment allocation.
(Continued on next page)
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Discussion: The 35/39 trial is powered to detect an effect of induction of labour on the risk of caesarean section, it is
underpowered to determine whether it improves perinatal outcome. The current study will also act as a pilot for a
larger study to address this question.
Trial registration: ISRCTN11517275
Keywords: Induction of labour, Advanced maternal age, Perinatal outcome, Caesarean delivery
Background
The average age at childbirth in the UK is increasing,
and more women are giving birth over the age of
35 years [1]. In 1996, 12% of live births were to women
over the age of 35 years. By 2006 that figure had risen
to 20%. The Office of National Statistics estimate that
in 2006, 5.6% of live births were to nulliparous women
over the age of 35 years. In Scotland, the figure in 2005
was approximately 10% [2].
Women over 35 years are at higher risk of antepartum
and intrapartum stillbirths and neonatal deaths, of hyper-
tensive disorders, gestational diabetes, placenta praevia
and placental abruption [3-5]. They are at increased risk
of preterm labour and of bearing macrosomic (>3999 g)
or low birth weight infants (<2500 g). The women them-
selves typically believe that their age puts their infant at
increased risk [4]. Unsurprisingly they have higher rates of
obstetric intervention.
The Caesarean section rate for nulliparous women
over 35 years is 38% and 50% in women over 40 years
[4]. In nulliparous women, the relationship between ma-
ternal age and delivery by emergency Caesarean is linear
which suggests a biological effect of advancing maternal
age on labour performance, rather than simply obstetri-
cian or maternal preference [2].
Antepartum stillbirth is particularly important in this
group of women, because they are relatively unlikely to
have future pregnancies. Induction at or before term is
logical because, although the perinatal mortality rate is
lowest at 41 weeks, the gestational age associated with
the lowest cumulative risk of perinatal death is
38 weeks [6]. This is because there is a cumulative risk
of stillbirth in all of the weeks of gestation leading up
to the eventual week of delivery. The largest increase
in risk of stillbirth for women over 35 years of age
starts at 39 weeks and peaks at 41 weeks. Women
over 40 years old have a similar stillbirth risk at
39 weeks as women aged 25–29 years old have at
41 weeks. Once they pass 40 weeks gestation their
risk of stillbirth exceeds that of all women <40 years
old at term [7]. Nulliparous women have a higher risk
of stillbirth than multiparous women for all maternal
age groups. Obstetricians and parents generally
understand this, but may avoid routine induction be-
cause of its association with Caesarean section.
Emergency Caesarean sections carry an increased ma-
ternal morbidity and mortality compared to vaginal de-
livery and have consequences for future pregnancies
(uterine rupture and placenta praevia). Caesarean sec-
tions cost £760 more than a vaginal delivery [8]. A re-
cent trial of induction of labour at term for women
identified as high risk for emergency CS (higher the
risk score, earlier the induction), found in the treat-
ment group a similar CS rate, a higher vaginal birth
rate and a reduced NICU admission and adverse peri-
natal outcome rate [9].
Perinatal deaths affect 0.8% of all pregnancies to
women over the age of 35 years, and 1% of all pregnan-
cies to women over the age of 40 years [3]. The distri-
bution of maternal age among the mothers having
perinatal deaths is skewed towards advanced maternal
age compared with the general maternity population.
Mothers having stillbirths and neonatal deaths are
more likely to be older (40+). When an adverse event
is rare, a large sample size is needed for a trial to prove
that an intervention reduces the risk of that adverse
event occurring.
Many obstetricians already induce older pregnant
women at term (39% women aged 40–44, 58% women
aged over 45), and many others believe that induction
would improve perinatal outcomes but are reluctant to
offer it for fear of increasing Caesarean rates [10]. How-
ever, it is equally plausible that induction might reduce
Caesarean section in which case an effective intervention
is being under implemented.
There is a growing body of evidence that induction of
labour at term does not increase emergency Caesarean
section rates and does not increase intrapartum deaths.
In two other large multi-centre RCTs where induction of
labour was compared with expectant management for
term prelabour rupture of membranes and for post-term
pregnancies, a policy of induction did not increase the
Caesarean section rate [11,12]. More recently a large
randomised controlled trial comparing induction of
labour (between 36 and 41 weeks) versus expectant
management for women with gestational hypertension
or mild pre-eclampsia found that the rate of Caesarean
delivery was the same in both groups [13]. Induction
versus expectant monitoring for intrauterine growth
restriction at term, a multi-centre RCT of 650 women
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found no difference in CS rates between the two groups
[14].
Unfortunately there is no hard evidence to guide po-
licy on induction of labour for advanced maternal age.
Design
Type of study
A multi-centre prospective randomised controlled trial.
Duration: 24 months
Number and type of participants
630 nulliparous pregnant women over 35 years of age
(315 per group).
Recruitment and consent
Women will be identified in the antenatal period by their
obstetrician or midwife. They will be offered an information
sheet. They will be offered trial entry, and if they agree will
sign a written consent. Women who are aged between
35–39 years at some of the participating centres will be
community led care. Those women will be sent an invi-
tation flyer or leaflet with their dating scan appoint-
ment to inform them of the trial and approached in
person at their 20/40 anomaly scan at the hospital. The
research midwives/principal investigator will see those
women who express an interest in joining the trial at
36/40 for randomisation.
Randomisation
Participants will be assigned to one of two treatment
groups via a computerised randomisation programme at
the Clinical Trials Unit, Nottingham University Hospitals
NHS Trust. Randomisation will occur at 360/7 – 396/7
weeks gestation.
Interventions
Women will be randomly allocated to one of two groups
 Treatment group: Women over the age of 35 years
with a singleton live fetus in a cephalic presentation
will be assigned to induction of labour between 390/7
and 396/7 weeks gestation.
 Control group: Women over the age of 35 years
with a singleton live fetus in a cephalic
presentation will be assigned to expectant
management i.e. awaiting spontaneous onset of
labour unless a situation develops necessitating
either induction of labour or Caesarean Section.
Those without any medical indication for
induction will be offered induction of labour
anywhere between T+7 and T+14, the exact time to
be determined by consultant’s usual practice. No
additional monitoring in the expectant
management group prior to T+14 should be offered
unless it is the consultant’s usual practice. If the
patient declines induction of labour at T+14 the
patient will be offered a scan for growth and liquor
volume and offered alternate day or daily CTG
monitoring depending on the consultants usual
practice.
This is a pragmatic clinical trial where individual units
will be able to follow their own policies for induction of
labour. Each unit will record their local prostaglandin
and oxytocin regime and Bishop score cut-off for
amniotomy, prior to entry to the trial. Once this is
recorded staff should as far as possible use the same in-
duction protocol for all participants and also for those
women who for whatever reason require induction in
the “await spontaneous labour” group.
Outcome measures
The primary end point is Caesarean section.
Secondary end points will include:
a) Maternal outcomes
Mode of delivery
Vaginal delivery
Assisted vaginal delivery (forceps or ventouse)
Caesarean section
Onset of labour
Spontaneous
Induction
Planned Caesarean section
Not in labour - emergency Caesarean section
Indication for induction of labour
Randomised to treatment
Gestational age > 41 weeks
Preterm (< 37 weeks) prelabour rupture of membranes
Term (> 37 weeks) prelabour rupture of membranes >
24 hours
Fetal growth restriction
Reduced fetal movements
Intrauterine fetal death
Pregnancy induced hypertension
Pre-eclampsia
Eclampsia
Obstetric cholestasis
Gestational diabetes
Suspected fetal distress
Maternal request
Other (free text)
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Method of induction of labour (as many as apply)
Prostaglandin tablet regime
Prostaglandin gel regime
Prostaglandin slow-release pessary
Artificial rupture of amniotic membranes
Oxytocin (please do not tick if used to accelerate
normal labour)
Indication for Caesarean section
Arrest of first stage of labour
Arrest of second stage of labour
Failed instrumental delivery
Fetal distress
Maternal complication
Elective
Other (free text)
Intrapartum complications
Placental abruption
Cord prolapse
Postpartum haemorrhage
Shoulder dystocia
Postpartum morbidity
Requiring blood transfusion
Systemic infection – temp > 38°C
b)Neonatal outcomes
Live birth
Stillbirth (a baby delivered with no signs of life after
24 completed weeks of pregnancy)
Birth weight
Sex
Death before discharge from hospital
Apgar at 1 min
Apgar at 5 min
Apgar at 10 minutes – allow missing data
Cord blood artery pH and BD – allow missing data
Cord blood vein pH and BD – allow missing data
NICU admission – duration (days)
If no cord blood and NICU admission required –
first fetal pH obtained
Birth trauma
Subdural haematoma
Intracerebral or intraventricular haemorrhage
Spinal-cord injury
Basal skull fracture
Peripheral-nerve injury present at discharge from
hospital
Long bone fracture
Seizures (occurring at less than 24 hr of age or
requiring two or more drugs to control them)
Hypotonia (for at least 2 hrs)
Abnormal level of consciousness (hyperalert, drowsy
or lethargic; stupor/decreased response to pain;
coma)
Tube feeding for > 4 days
Intubation and ventilation for > 24 hrs
Cooling required
Oxygen required
CPAP required
c) Outcomes for pilot study
The recruitment rate per hospital.
The age distribution of participating women.
Compliance with the treatment arms of the trial.
The overall gestational age distribution of the two
groups.
Completeness of outcome data.
d)Maternal delivery expectation/experience measured
by the Childbirth Experience Questionnaire [15]. We
will invite a sample of participants to join focus
groups to explore in-depth their views.
Participant entry
Pre-randomisation evaluations
Blood pressure and urinalysis to exclude proteinuric
hypertension.
Estimated date of delivery based on a dating scan per-
formed before 22 weeks gestation.
Inclusion criteria
Nulliparous women who will be over 35 years at the
expected date of delivery, with:
 A singleton live fetus.
 A cephalic presentation.
 Gestational age between 360/7 and 396/7.
 No medical contra-indication to induction of labour.
 No medical contra-indication to pregnancy being.
allowed to proceed to term plus 10 days.
 Willingness to participate in the trial.
 Written informed consent.
Exclusion criteria
Women with a known lethal fetal congenital abnormality.
Women with a contraindication to labour or vaginal
delivery (e.g. evidence of fetal compromise such that
labour would be contraindicated; fetal congenital anom-
aly or condition that might cause a mechanical problem
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at delivery such as hydrocephalus or cystic hygroma; pla-
centa praevia).
Women with a contraindication to expectant manage-
ment (e.g. gestational diabetes, proteinuric hypertension
(24 hr urine collection protein >250 mg/l or BP > 140/90
on more than two occasions, two hrs apart).
Women with a previous myomectomy.
Women who book late for antenatal care and have no
dating scan performed before 22 weeks to provide an
accurate EDD.
Women who have undergone IVF using donor eggs in
the current pregnancy.
Withdrawal criteria
There are no formal stopping rules. The Data Monitoring
and Ethics Committee will review un-blinded results,
adverse events and any other published data at least annu-
ally, and may advise stopping if there is clear evidence of
benefit or harm in one or other group.
Adverse events
Definitions Adverse Event (AE): any untoward medical
occurrence in a patient or clinical study subject.
Serious Adverse Event (SAE): any untoward and unex-
pected medical occurrence or effect that:
 Results in death.
 Is life-threatening – refers to an event in which the
subject was at risk of death at the time of the event;
it does not refer to an event which hypothetically
might have caused death if it were more severe.
 Requires hospitalisation, or prolongation of existing
inpatients’ hospitalisation.
 Results in persistent or significant disability or
incapacity.
 Is a congenital anomaly or birth defect.
Medical judgement should be exercised in deciding
whether an AE is serious in other situations. Important
AEs that are not immediately life-threatening or do not
result in death or hospitalisation but may jeopardise the
subject or may require intervention to prevent one of
the other outcomes listed in the definition above, should
also be considered serious.
Reporting procedures
All adverse events should be reported. Depending on the
nature of the event the reporting procedures below
should be followed. Any questions concerning adverse
event reporting should be directed to the Chief Investi-
gator in the first instance.
Non-serious AEs
All such events, whether expected or not, should be
recorded.
Serious AEs
An SAE form should be completed and faxed to the
Chief Investigator within 24 hours. However, adverse
events do not include admissions or day unit attendances
for fetal monitoring, maternal hypertension, antepartum
haemorrhage, preterm labour, preterm prelabour rupture
of membranes, abdominal pain, transverse or oblique lie
or placenta praevia. Likewise hospitalisation for labour,
normal delivery, Caesarean or for induction of labour, and
hospitalisations for elective treatment of a pre-existing
condition do not need reporting as adverse events.
Admissions for common postpartum complications such
as maternal hypertension, perineal problems, mental
health problems, urinary problems, or infections do not
need reporting as adverse events.
All SAEs should be reported to the Derby 1 REC
where in the opinion of the Chief Investigator, the event
was:
 ‘related’, i.e. resulted from the administration of any
of the research procedures; and
 ‘unexpected’, i.e. an event that is not listed in the
protocol as an expected occurrence.
Reports of related and unexpected SAEs should be
submitted within 15 days of the Chief Investigator be-
coming aware of the event, using the NRES SAE form
for non-IMP studies.
Local investigators should report any SAEs as required
by their Local Research Ethics Committee and/or Re-
search & Development Office.
Sponsor Contact Details for SAEs:
1. Email to rdsae@nhs.nuh.uk,
2. Fax to: 0115 8493295 and phone Research &
Innovations Dept on 0115 9709049.
Assessment and follow-up
Post-randomisation data will be collected at discharge.
Local centres will identify an individual within their
unit to collect outcome data at hospital discharge from
the hospital notes. Outcome data will be collected im-
mediately following discharge by the same individual
identified above.
Part of the outcome data will include a maternal ex-
pectation/experience questionnaire to be completed by
mothers one month following delivery [15].
Participating women who deliver at NUH will also be
invited to join a focus group to explore in-depth their
views. The information obtained from the focus groups
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will allow us to collect richer outcome data from the
trial that will allow a more in-depth contextual appre-
ciation of the participants experience than a prescriptive
survey would allow. The focus groups will be conducted
by Kate Walker supervised by Associate Professor in
Midwifery Denis Walsh who has agreed to be a co-
supervisor on her PhD and will take place within 8 to
12 weeks following birth. This allows for women to re-
flect upon their birth as well as recover from it.
The focus groups will be split into two subgroups:
women who underwent induction of labour and women
who were part of the non-intervention group who
underwent expectant management.
We will aim for 6 women per group.
The focus groups aim to provide a comprehensive sense
of the acceptability of this treatment option to women.
The trial will end once all data has been collected for
the 630 participants or at 2 years whichever is the later
time point.
Statistics and data analysis
Sample size and justification CS rates from 2004–2008
for women with singleton pregnancies in labour at term,
excluding breech presentation was approximately 22%
among women 35–39 years of age and approximately 27%
among women aged 40 years or older (Smith GCS,
personal communication).
Therefore assuming a Caesarean section rate of 25% in
controls. This sample size has 80% power with a two-sided
significance level of 5% to test the hypothesis that induction
of labour reduces the Caesarean section rate to 16%, a 36%
relative reduction (or a 9% absolute reduction).
We will recruit 315 women per group, a total of
630 women.
Statistical analysis
Demographic, measures of compliance and any other
baseline data will be summarised by descriptive statistics
(N (%), mean and standard deviation [sd], median, upper
and lower quartiles {iqr}, minimum and maximum) or
frequency tables, stratified by the two arms.
Effectiveness will be assessed using a generalised linear
model (GLM) with the rate of Caesarean section as
response and terms for treatment arm and centre. We will
use the GLM to calculate relative risk and 95% confidence
intervals. The primary analysis will be adjusted for recruit-
ment centre.
Further details of the statistical analysis will be sup-
plied in the Statistical Analysis Plan, to be finalised in a
separate document before the data lock.
The analysis will be conducted according to the
intention to treat (ITT).
Data and all appropriate documentation will be stored
for a minimum of 5 years after the completion of the
study, including the follow-up period.
Regulatory issues
Ethics approval The Chief Investigator has obtained
approval from the Derby 1 Research Ethics Committee.
Where applicable the study must be submitted for Site
Specific Assessment (SSA) at each participating NHS
Trust. The Chief Investigator will require a copy of the
SSA approval letter before accepting participants into
the study. The study will be conducted in accordance
with the recommendations for physicians involved in
research on human subjects adopted by the 18th World
Medical Assembly, Helsinki 1964 and later revisions.
Consent
Consent to enter the study must be sought from each
participant only after a full explanation has been given,
an information leaflet offered and time allowed for
consideration. Signed participant consent should be
obtained. The right of the participant to refuse to par-
ticipate without giving reasons must be respected. After
the participant has entered the study the clinician
remains free to give alternative treatment to that speci-
fied in the protocol at any stage if he/she feels it is in
the participant’s best interest, but the reasons for doing
so should be recorded. In these cases the participants
remain within the study for the purposes of follow-up
and data analysis. All participants are free to withdraw
at any time from the protocol treatment without giving
reasons and without prejudicing further treatment.
Confidentiality
The Chief Investigator will preserve the confidentiality
of participants taking part in the study and is registered
under the Data Protection Act.
Indemnity
Standard NHS Indemnity applies.
Sponsor
Nottingham University Hospitals NHS Trust will act as
the main sponsor for this study. Delegated responsibi-
lities will be assigned to the NHS trusts taking part in
this study.
Funding
The National Institute for Health Research – Research
for Patient Benefit Programme is funding this study.
Audits
The study may be subject to inspection and audit by
Nottingham University Hospitals under their remit as
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sponsor and other regulatory bodies to ensure adherence
to GCP and the NHS Research Governance Framework
for Health and Social Care (2nd edition).
Study management
The day-to-day management of the study will be co-
ordinated through the Trial Manager – Dr Kate Walker
supported by the Trial Management Group (Professor
Jim Thornton, Mr George Bugg, Miss Marion Macpher-
son, Professor Gordon Smith, Miss Carol McCormick,
Mrs Nicky Grace and Mr Chris Wildsmith).
The Trial Steering Committee (TSC) will provide over-
all supervision of the trial including trial progress, adher-
ence to the protocol, patient safety and consideration of
new information arising during the period of recruit-
ment to the trial.
The Data Monitoring and Ethics Committee (DMEC)
will meet regularly to review un-blinded data.
Publication policy
All papers will be authored by the “35/39” trial study
group. All contributors will be fully acknowledged.
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